Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15738 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Erkka Järvinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Warfarin, Dicloxacillin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden.
Abstract (Originalsprache)
Aims
Dicloxacillin is used to treat staphylococcal infections and we have previously shown that dicloxacillin is an inducer of cytochrome P450 enzymes (CYPs). Here, we employed a translational approach to investigate the effect of a treatment with dicloxacillin on warfarin efficacy in Danish registries. Furthermore, we assessed dicloxacillin as an inducer of CYPs in vitro.
Methods
We conducted a register‐based study and analysed international normalized ratio (INR) levels in chronic warfarin users before and after short‐ and long‐term use of dicloxacillin ( n = 1023) and flucloxacillin ( n = 123). Induction of CYPs were investigated in a novel liver model of 3D spheroid primary human hepatocytes at the level of mRNA, and protein and enzyme activity.
Results
Short‐ and long‐term dicloxacillin treatments decreased INR levels by −0.65 (95% confidence interval [CI]: −0.57 to −0.74) and −0.76 (95% CI: −0.50 to −1.02), respectively. More than 90% of individuals experienced subtherapeutic INR levels (below 2) after long‐term dicloxacillin treatment. Flucloxacillin decreased INR levels by −0.37 (95% CI: −0.14 to −0.60). In 3D spheroid primary human hepatocytes, the maximal induction of CYP3A4 mRNA, protein and enzyme activity by dicloxacillin were 4.9‐, 2.9‐ and 2.4‐fold, respectively. Dicloxacillin also induced CYP2C9 mRNA by 1.7‐fold.
Conclusion
Dicloxacillin induces CYPs and reduces the clinical efficacy of warfarin in patients. This effect is substantially exacerbated during long‐term treatment with dicloxacillin. The in vitro results corroborated this drug–drug interaction and correlated to the clinical findings. Caution is warranted for warfarin patients that initiate dicloxacillin or flucloxacillin, especially for a long‐term treatment of endocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- SIGNATOPE GmbH, Reutlingen, Germany.
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Erkka Järvinen, Ann-Cathrine Dalgård Dunvald, Anton Pottegård, Tore B Stage
Förderung
- Novo Nordisk Fonden
Zitieren
APA
Järvinen, E., Dalgård Dunvald, A. C., Ernst, M. T., Hammer, H. S., Pötz, O., Pottegård, A., & Stage, T. B. (2023). Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15738
Vancouver
Järvinen E, Dalgård Dunvald AC, Ernst MT, Hammer HS, Pötz O, Pottegård A, et al. Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15738
BibTeX
@article{Jrvinen2023,
author = {Järvinen, Erkka and Dalgård Dunvald, Ann-Cathrine and Ernst, Martin Thomsen and Hammer, Helen S and Pötz, Oliver and Pottegård, Anton and Stage, Tore B},
title = {Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15738}
}
EUVIMED